A Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Phase 2 Study of Efficacy and Safety of Tirzepatide in Individuals With Alcohol Use Disorder and Metabolic Alcohol-associated Liver Disease
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Metabolic improvement from baseline as measured by percentage reduction of body weight and reduction in liver steatosis from baseline as measured by percentage reduction in Fibroscan controlled attenuation parameter (CAP) score.
研究概览
简要总结
Background:
People with alcohol use disorder (AUD) often develop metabolic alcohol-associated liver disease (MetALD). MetALD is a term for the heart, liver, obesity, and other issues that can accompany AUD. MetALD can be fatal. An approved weight management drug (Tirzepatide) may be able to help people with AUD and MetALD control their alcohol intake.
Objective:
To test Tirzepatide in people with AUD and MetALD.
Eligibility:
People aged 21 years and older with AUD and MetALD.
Design:
Participants will be screened. They will have a physical exam with blood and urine tests. They will have a test of their heart function. They will have a Fibroscan: This test uses ultrasound to measure how stiff the liver is. They will answer questions about their alcohol drinking, eating habits, and mental health. Participants may opt to have imaging scans of their brain and liver.
These tests will be repeated in a baseline visit. This visit will take up to 6 hours.
Tirzepatide is injected under the skin once a week for 12 weeks. Participants will visit the clinic to receive each injection. Some participants will get a placebo. A placebo is given just like a Tirzepatide injection but contains no medicine. The physical exam and other tests will be repeated during clinic visits. The Fibroscan will be repeated every 2 weeks during the study. Each weekly visit will take up to 3 hours.
All tests will be repeated on the last visit. These tests will include the imaging scans and Fibroscan. Participants will learn about treatment options for AUD; they will be given recommendations on ways to reduce alcohol intake. This visit will take up to 6 hours.
详细描述
STUDY DESCRIPTION:
The GLP-1/GIP receptor dual agonist tirzepatide has been recently shown to reduce HbA1c in adults with Type 2 diabetes, achieve weight reduction in adults with obesity and reduce metabolic dysfunction associated steatohepatitis. In addition, some data suggest beneficial effects on drinking behaviors. This study will evaluate the efficacy and safety of tirzepatide as a novel treatment for alcohol use disorder (AUD) and metabolic alcohol-associated liver disease (MetALD).
We hypothesize that tirzepatide will be well tolerated and safe in this new target population and that tirzepatide will achieve reduction in alcohol use, metabolic improvement and attenuate alcohol-induced liver steatosis.
OBJECTIVES:
Primary Objective:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 21 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •INCLUSION CRITERIA
- •To be eligible to participate in this study, an individual must meet all of the following criteria:
- •Age 21 or older
- •Ability to provide written informed consent
- •Females: Negative urine pregnancy test, not currently breastfeeding, agree to abstain or use accepted form of contraception including use of oral contraceptives and an additional barrier method of contraceptive such as condoms; use of an approved IUD or other longacting reversible contraceptive (LARC); have a male sexual partner who is surgically sterilized; or have exclusively female sexual partner(s)
- •Males: Agree to abstain or use accepted form of contraception, such as condoms.
- •Diagnosis of AUD as confirmed by MINI
- •Current alcohol use as assessed via the TLFB (>14 standard drinks per week for males and >7 standard drinks per week for females on average for the last 8 weeks)
- •Liver steatosis as determined by Fibroscan (CAP score >240) at screening
- •BMI >= 25 and <40 kg/m^2
- •metALD as defined by at least one out of 5 criteria at screening:
- •BMI >= 25 and <40 kg/m^2
- •Fasting serum glucose >= 5.6mmol/L [100mg/dL] or HbA1c >=5.7%
- •Blood pressure >=130/85 or specific antihypertensive drug treatment
- •Plasma triglycerides >=1.70mmol/L [150mg/dL] or lipid lowering treatment
- •Plasma HDL-cholesterol less than 1.0mmol/L [40mg/dL] or lipid lowering treatment
排除标准
- •An individual who meets any of the following criteria will be excluded from participation in this study:
- •Treatment seeking for alcohol use disorder
- •History of a serious hypersensitivity reaction to GLP-1RA/GIPRA
- •Current/past use of GLP-1RA/GIPRA within the last 3 months
- •Clinically significant and/or unstable cardiovascular disease over the past 12 months
- •History of diabetes mellitus or blood hemoglobin A1c (HbA1c) >= 6.5 % at screening
- •Any underlying clinically significant and/or unstable acute or chronic liver disease unrelated to alcohol use at screening, history of cirrhosis, esophageal varices
- •Subjects with platelets count of less than 110,000/ mm^3
- •Alanine aminotransferase or aspartate aminotransferase exceeding 5 times the upper limit of normal levels at screening
- •Bilirubin 2x UNL or Creatinine > 2 mg/dL at screening
- •Patients with coagulopathy defined as INR >1.5, prothrombin time prolonged by > 3s, and/or platelets <75,000 / mm^3 at screening
- •Positive HIV test or positive Hepatitis B surface antigen (HBsAg), and/or positive Hepatitis C antibody (HCV) at screening
- •Chronic renal failure as estimated by glomerular filtration rate (GFR) < 60mL/min/1.73 m^2 at screening
- •History of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- •History of previous bariatric surgery or transplant surgery
- •Patients with significant hematologic abnormalities, as defined by hemoglobin < 8g/dL and/or white blood count <1500 cells/microL
- •Current or prior history of any clinically significant disease, including, seizure disorder, epilepsy, alcohol related seizures within 12 months of screening, uncontrolled endocrine disease, hemorrhagic stroke, cancer within the past 5 years or any other significant abnormality identified at the time of screening that, in the judgment of the investigator or study clinician, would preclude safe completion of the study
- •Use of any medications that interfere with tirzepatide
- •Use of the following medications with glucose lowering properties in the last 30 days: GLP-1RA, GLP-1RA/GIPRA, insulin, metformin, sulfonylurea, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors
- •Use of the following medications: Any medication that requires intramuscular administration injections. Systemic corticosteroids
- •Use of any investigational drugs within 1 month, or five half-lives, whichever is longer, of the study procedures
- •Presence of any current suicidality or a lifetime history of suicide attempt or suicidal ideation within the past year
- •History of serious mental illnesses including psychotic disorders, bipolar disorders, severe anxiety, mood, or trauma-related disorders and other psychiatric conditions which in the opinion of the investigators would impede the patient's participation or compliance in the study
- •History of liver decompensation events such as hepatic encephalopathy or ascites
- •History of severe gastroparesis
- •History of pancreatitis in the last 5 years or if subject has chronic pancreatitis
- •For optional MRI: a) Presence of ferromagnetic objects in the body that may be adversely affected by or contraindicated for MRI, fear of enclosed spaces, or other standard contraindication to MRI, as determined by self-report b) Use of MRI- incompatible intrauterine device (IUD).
- •Individuals who are pregnant or breastfeeding, or with severe hepatic or renal liver impairment will be excluded from this study because there is no clinical data on the safety of tirzepatide in these populations, including the impact on the fetus or infant. To assess pregnancy status, participants who can become pregnant will be required to take a urine pregnancy test and to test negative before administering study drug.
研究组 & 干预措施
Saline
A 2.5mg, 5mg, and 7.5mg subcutaneous injection will be given once weekly for 12 weeks.
干预措施: Placebo (Other)
Tirzepatide
A 2.5mg, 5mg, and 7.5mg subcutaneous injection will be given once weekly for 12 weeks.
干预措施: Tirzepatide (Drug)
结局指标
主要结局
Metabolic improvement from baseline as measured by percentage reduction of body weight and reduction in liver steatosis from baseline as measured by percentage reduction in Fibroscan controlled attenuation parameter (CAP) score.
时间窗: Change from baseline to week 12
次要结局
- Reduction from baseline in - 1) Liver steatosis as measured by MRI spectroscopy, 2) MRI visceral fat, 3) Liver enzymes (ALT, AST, GGT), 4) Drinking behaviors/cravings, 5) WHO risk drinking level(Change from baseline to week 12)